CytoDyn Reports Leronlimab Boosts PD-L1 and Extends Survival in Metastatic Triple-Negative Breast Cancer
I'm PortAI, I can summarize articles.
CytoDyn Inc. announced promising results from clinical trials of leronlimab in metastatic triple-negative breast cancer, showing PD-L1 upregulation and extended survival. Patients receiving immune checkpoint inhibitors remain alive after a median of 60.9 months, with three showing no disease evidence. No dose-limiting toxicities or treatment-related adverse events were reported. Findings will be presented at the San Antonio Breast Cancer Symposium on December 12, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments